A pilot randomised controlled trial of a structured, home-based exercise programme on cardiovascular structure and function in kidney transplant recipients: the ECSERT study design and methods

Roseanne E Billany, Noemi Vadaszy, Nicolette C Bishop, Thomas J Wilkinson, Sherna F Adenwalla, Katherine A Robinson, Kathryn Croker, Emer M Brady, Joanne V Wormleigh, Kelly S Parke, Nicola J Cooper, Angela C Webster, Jonathan Barratt, Gerry P McCann, James O Burton, Alice C Smith, Matthew PM Graham-Brown.

ABSTRACT

Background Cardiovascular disease (CVD) is a major cause of morbidity and mortality in kidney transplant recipients (KTRs). CVD risk scores underestimate risk in this population as CVD is driven by clustering of traditional and non-traditional risk factors, which lead to prognostic pathological changes in cardiovascular structure and function. While exercise may mitigate CVD in this population, evidence is limited, and physical activity levels and patient activation towards exercise and self-management are low. This pilot study will assess the feasibility of delivering a structured, home-based exercise intervention in a population of KTRs at increased cardiometabolic risk and evaluate the putative effects on cardiovascular structural and functional changes, cardiorespiratory fitness, quality of life, patient activation, healthcare utilisation and engagement with the prescribed exercise programme.

Methods and analysis Fifty KTRs will be randomised 1:1 to: (1) the intervention; a 12-week, home-based exercise programme; or (2) the control; usual care. Intervention participants will have one introductory session for instruction and practice of the recommended exercises prior to receiving an exercise diary, dumbbells, resistance bands and access to instructional videos. The study will evaluate the feasibility of recruitment, randomisation, retention, assessment procedures and the intervention implementation. Outcomes, to be assessed prior to randomisation and postintervention, include: cardiac structure and function with stress perfusion cardiac MRI, cardiorespiratory fitness, quality of life, patient activation, healthcare utilisation and engagement with the prescribed exercise programme.

Strengths and limitations of this study

- Data on the effects of exercise interventions on the cardiac structural and functional aspects of cardiovascular disease in this population are lacking and baseline values of multiparametric cardiac MRI in kidney transplant recipients are previously undefined.
- This study uses a novel home-based exercise intervention with the potential to translate into a widespread, low-resource intervention compared with in-centre, supervised interventions that are costly and labour intensive.
- As it can be difficult to ensure control groups are not influenced to change their lifestyle as a result of being part of the study, control participants will be offered the intervention after completion of the study.
- This study will provide quantitative and qualitative feasibility and pilot data to inform a definitive randomised controlled trial that will explore longer term engendered lifestyle change in this population in response to a complex, home-based, lifestyle intervention.
- Secondary outcome analysis will identify the putative cardiometabolic and muscular effects of the intervention, although these results would need confirming in adequately powered studies due to the small sample size of this pilot study.

EM/0209; 14 October 2019. Results will be published in peer-reviewed academic journals and will be disseminated to the patient and public community via social media, newsletter articles and presentations at conferences.

Trial registration number NCT04123951.
BACKGROUND

Kidney transplantation is the preferred modality of renal replacement therapy for patients with end-stage kidney disease (ESKD). Although kidney transplantation confers a significant survival advantage over remaining on dialysis, cardiovascular disease (CVD) is a leading cause of morbidity, mortality and graft loss. Since 2015, mortality rates attributed to CVD have been rising in kidney transplant recipients (KTRs) associated with traditional cardiometabolic risk factors, which drive classical atheromatous coronary artery disease, and non-traditional risk factors resulting in pathological changes in cardiovascular structure and function that associate with mortality. Immunosuppressive agents are well known to drive traditional and non-traditional cardiometabolic risk factors. Non-traditional cardiometabolic risk factors, including endothelial dysfunction, systemic inflammation, acute rejection, anaemia and deranged bone mineral metabolism, are of at least equal importance in the pathogenesis of CVD in KTRs. This is further illustrated by the fact that traditional CVD risk stratification tools dramatically underestimate cardiovascular risk in patients with chronic kidney disease (CKD). Coronary revascularisation does not improve outcomes for KTRs as it does in the general population and cardiac events are more likely to be fatal in KTRs.

CKD-related cardiomyopathy, which has been termed ‘Uremic Cardiomyopathy’, is characterised by stereotypical changes in the cardiovascular structure and function of the heart such as left ventricular hypertrophy (LVH), left ventricular dilatation, left ventricular systolic dysfunction, myocardial fibrosis and aortic stiffness, all of which relate to poor cardiovascular outcomes. Although structural and functional improvements of the heart and vessels have been seen post-transplantation in some studies, others have shown no regression and parameters such as LVH are independent factors for cardiac failure and mortality in KTRs. Cardiac MRI (CMR) is the gold standard for assessment of ventricular structure and function and we have shown methods for assessment of tissue characterisation, aortopathy and subclinical systolic and diastolic function to be reproducible in patients with kidney disease, making CMR the ideal imaging modality for assessing multiple aspects of prognostically relevant measures of CVD in clinical studies.

Numerous epidemiological studies have observed the association between low levels of physical activity and increased prevalence of CVD risk factors and an inverse relationship between physical activity and all-cause and CVD mortality. Physical activity levels in KTRs are lower than the general population, with only 27% classified as meeting the UK national recommended physical activity levels. While physical activity levels improve in the year following transplantation, they plateau after 1 year. In the general population, lifestyle changes that increase physical activity through structured exercise lower mortality. Despite this evidence, there is a lack of rigorous research into the role of increased physical activity in mitigating cardiovascular risk in KTRs. Recent consensus recommendations from experts and stakeholders highlighted the need for a priority research agenda in exercise for solid organ transplant recipients to improve cardiovascular outcomes in this patient population. While supervised exercise interventions in KTRs improve cardiorespiratory fitness and a variety of traditional and non-traditional risk factors for CVD, including metabolic profile, strength, vascular stiffening, weight and inflammation, they are not realistically deliverable in the current financial climate and have not translated to clinical practice. Furthermore, exercise habits following in-centre supervised programmes are not maintained which can be potentially attributed to low levels of patient activation (a measure of a person’s skills, confidence and knowledge to manage their own health) and a failure for such programmes to engender sustained lifestyle changes.

Home-based exercise training programmes have been shown to be deliverable in patients on dialysis and patients undergoing cardiac rehabilitation, but the effectiveness and deliverability of home-based exercise interventions are largely untested in KTRs. It cannot be assumed that such programmes will be acceptable to KTRs, whose home lives and social and occupational circumstances are significantly different from dialysis and cardiac patients. Many KTRs have had enforced sedentary lifestyles prior to transplantation as dialysis patients and their goals for rehabilitation as well as the disease processes at work may be different.

Objectives

The aims of this study are to evaluate the impact of a 12week, home-based exercise intervention in KTRs with increased cardiometabolic risk, specifically addressing:

- The deliverability and feasibility of the home-based exercise intervention in KTRs, defining recruitment, retention, compliance and adverse events (AE).
- Potential cardiovascular structural and functional parameters measured using stress perfusion CMR.
- Cardiorespiratory fitness and strength.
- Biochemical markers of cardiometabolic health, body composition, physical function and quality of life.
- Patient activation and continued adherence to the prescribed home-based exercise programme.

Two substudies will assess:

- The acceptability of the intervention through qualitative semistructured interviews postintervention.
- The differences between cardiorespiratory fitness in ‘healthy controls’ without a kidney transplant versus KTRs.

METHODS AND ANALYSIS

ECSERT trial design

This study is a prospective, randomised, open-label, blinded endpoint pilot study. The study flow chart is presented in figure 1.
**Participant identification and recruitment**

Fifty KTRs with a stable kidney transplant of >1 year will be recruited from University Hospitals of Leicester NHS Trust (UHL) kidney transplant outpatient clinic lists. There are approximately 400–420 KTRs registered in UHL kidney transplant outpatient clinics.

Full lists of inclusion and exclusion criteria for KTRs are included in [table 1](#). Patients will be screened by a clinician for eligibility to enter the study. Eligible patients will be approached (via telephone, post or during their routine clinical appointment) and will be provided with verbal and written study information.

---

**Figure 1** ECSERT study flow diagram. CMR, cardiac MRI; KTR, kidney transplant recipient.
and time to consider without further contact (at least 24 hours). Additionally, eligible patients who have given prior consent to be contacted regarding research opportunities will be contacted via post. All patients will be given the opportunity to discuss the study in more detail and to consider their participation. Consent will be performed by the chief investigator (MG-B) according to the rules of good clinical practice. Inclusion and exclusion criteria for healthy controls are included in table 1.

### Randomisation

Following baseline assessment, participants will be randomly allocated (1:1) to either: (1) a 12-week, home-based combined resistance and aerobic exercise intervention (n=25); or (2) control (n=25; receiving usual care). Randomisation will be blocked (using computer-generated random permuted blocks with allocation concealment; https://www.sealedenvelope.com/simple-randomiser/v1/) to ensure periodic balancing. The clinical trials facilitator will perform the randomisation. Given the nature of the intervention, it is not possible for the participants to be blinded to their allocation.

### Intervention and comparator arms

**Intervention group: 12-week, home-based combined aerobic and resistance training**

The 12-week, home-based, structured exercise programme includes aerobic and resistance training (four to five sessions in total per week). Participants will be advised to complete a warm-up and cool-down prior to and following each session, respectively. Participants will continue to receive usual clinical care.

**Aerobic component**

The aerobic component of the intervention will be walking, jogging, cycling or similar, depending on resources available and participant preference. Participants will be asked to complete two to three sessions per week using a rating of perceived exertion (RPE) of 13–15 (somewhat hard) for 20–30 min. RPE will be collected throughout cardio-pulmonary exercise tests (CPET) and participants will be educated on its use during the instructional session(s). RPE will be used rather than heart rate for two reasons: (1) Many patients are on medication which impacts heart rate (eg, beta blockers). We therefore cannot ascertain a true maximal heart rate from the exercise test in order for them to safely (and reliably) monitor intensity this...
way without supervision. (2) This is a pragmatic decision based on the potential for translation into low-cost future studies and clinical practice. However, should participants in the trial already own a smart watch or heart rate monitor, we would not discourage them from using it if they desire.

**Resistance component**

The resistance component of the exercise intervention will include a combination of six to eight exercises per session chosen by the participant from a pool of 12 exercises (to provide variety) targeting upper and lower body and core muscle groups using free weights and/or resistance bands. The chosen pool of exercises include: squat, hip abduction, lunge, calf raise, side lunge, bicep curl, bent-over row, reverse fly, lateral raise, chest press, side bends and standing trunk rotation. Each exercise has modifications for different abilities and may be pragmatically adjusted or changed throughout the study as required. These exercises were chosen based on their ability to be modified, their subjective difficulty and their safety when being performed by participants new to exercise in an unsupervised environment. Participants will aim to complete six to eight resistance exercises twice a week (but not on consecutive days to allow appropriate recovery). Initially, they will be advised to complete one to two sets of 10 repetitions (at approximately 60% of estimated 1 repetition maximum (1RM)) gradually increasing to three to six sets of 10 repetitions over the study period with a minimum of 30 seconds rest between sets. The 1RM will be determined after randomisation by an exercise physiologist. These figures may be adjusted to accommodate different abilities and different rates of progression. Where equipment is limited (eg, participants reach the highest provided dumbbell weight), participants will be advised to increase the number of sets performed. The load chosen was based on previous research which suggests while heavier loads (>60% of 1RM) are favoured for increasing strength, the effect size is still larger for lighter loads (<60% of 1RM) and both are effective for increasing muscle size. It is important not to discourage inactive or inexperienced participants with very heavy loads. Participants will be provided with an exercise diary which includes additional instructions, dumbbells and resistance bands, and access to educational and instructional videos. Instructional videos will include: the importance of an active and healthy lifestyle, the importance of warming up and cooling down and how to do it, a reminder of how to use the RPE scale, demonstrations of each resistance exercise and information about the aerobic component (videos can be viewed here: https://www.youtube.com/playlist?list=PLwbE3AF9eJ_Vul5uoiFC9Ci8rkgKz5Nv). Participants will receive a telephone call from a member of the research team every 2 weeks in order to discuss the progression of the exercise and address any issues that may arise. Participants will also be able to contact the research team at any time they desire and will continue to attend any scheduled clinic appointments and take prescribed medication as normal.

**Control group: ‘Usual care’**

Participants in the control group will be asked to maintain their current lifestyle and exercise habits throughout the study. This includes continuing to attend any scheduled clinic appointments and taking prescribed medication as normal. As part of routine care, KTRs are recommended to take regular exercise and maintain a healthy lifestyle. This advice will be reiterated to patients in the control group to ensure the intervention is being appropriately compared with best practice standard care. Participants will be asked to complete a ‘control diary’ to note any exercise, medication changes, illness and other relevant information. Once control participants complete the postintervention assessments, they will be offered the opportunity to complete the same intervention as the exercise group.

**Study timeline**

**Baseline assessments**

The ECSERT study timeline is shown in figure 1. Baseline assessments described below will be carried out on the same day where possible and in conjunction with routine clinical appointments to prevent additional travel.

**Collection of routine clinical information and cost-effectiveness**

Clinical information will be extracted from the medical notes including: age, gender, ethnicity, primary cause of kidney failure, transplant type, transplant vintage, dialysis duration, comorbidities, blood/urine results, current medication and smoking habits. This information will be used to primarily capture confounding variables and during analyses of differences and similarities between groups.

A questionnaire will be administered at baseline to capture the previous 3 months of self-reported healthcare utilisation including: inpatient and outpatient appointments, emergency care, community and primary care services, support services and changes in medications. This will be compared with data gathered from healthcare records allowing validation of the questionnaire for future cost-effectiveness analyses.

**Cardiac stress MRI**

All participants will undergo a comprehensive adenosine stress perfusion CMR scans at baseline and on study completion. Participants will be scanned on a 3T platform (Skyra, Siemens Medical Imaging, Erlangen, Germany) with an 18-channel phased array receiver coil. New-generation gadolinium-based contrast agent with a licence for use in patients with an (estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m²) will be given for perfusion and delayed enhancement imaging. Patients with an eGFR <40 mL/min/1.73 m² will undergo non-contrast CMR scanning without gadolinium. Scans will quantitatively define:

- Left and right ventricular structures and functions (left ventricular mass, left and right ventricular volumes and ejection fractions).
monitor (Moxy, Fortiori Design, Minnesota, USA) will be used to measure (VO₂ peak) using a simultaneous gas analyser (Metalyser 3B CPX System, CORTEX, Germany) as true maximal (plateau) VO₂ (VO₂max) is less commonly achieved in deconditioned and/or clinical patients. Test data will be considered usable if respiratory exchange ratio is ≥1.00 and RPE is ≥18. The test will be in the presence of a cardiac nurse to confirm safety to commence exercise training. Blood pressure will be assessed at baseline and every 2min throughout the test. A continuous 12-lead ECG will be monitored throughout. A non-invasive monitor (Moxy, Fortiori Design, Minnesota, USA) will be worn on the quadriceps muscle which uses near-infrared spectroscopy to measure local oxygen saturation (SmO₂) and total haemoglobin of the muscle.

Lower limb strength and muscular endurance
Isometric and isokinetic muscle (knee extension) strength of the dominant leg will be assessed using a dynamometer (Biodex System 4, Biodex Medical Systems, New York, USA). Peak isometric strength (torque, Nm) will be assessed from three repetitions of maximum effort at 90° knee flexion for ~3–5 s with 60 s rest. Isokinetic strength will be assessed at three speeds for one set of five repetitions at each speed: 60°/s, 90°/s, 120°/s. Participants will perform a ‘sit-to-stand-60’ (STS-60) test measuring how many sit-to-stand cycles can be performed over 60 s to assess lower limb muscular endurance.

Hand grip strength
Peak grip strength of the left and right hands will be assessed with a hand dynamometer (Jamar Plus; Sammons Preston, Bolingbrook, Illinois). Each hand will be alternatively tested for three attempts each and the highest value on each hand with be recorded.

Gait speed
A 4 m walk test will be used to assess gait speed. Participants will be asked to walk 4 m at their ‘usual walking pace’ for one practice and two timed trials. The average score (m/s) of the timed trials will be recorded.

Functional mobility
The ‘timed-up-and-go’ (TUAG) test will be used to assess functional mobility. The participant is timed while rising from the seated position on a chair, walking 3 m, turning around and returning to a seated position.

Balance and postural stability
Postural stability and balance will be assessed using a previously reported method with a FysioMeter device (modified Nintendo Wii balance board (Nintendo, Kyoto, Japan)) connected via Bluetooth to software on a portable computer (FysioMeter, Bronderslev, Denmark). Total centre of pressure ellipse area (mm²) will be obtained.

Quadriceps ultrasound and myotonometry
Rectus femoris anatomical cross-sectional area will be measured from the right leg using B-mode 2D ultrasoundography (Hitachi EUB-6500; probe frequency, 7.5 MHz) under resting conditions with the participant lying prone at 45° as previously described. Rectus femoris and vastus lateralis thickness, subcutaneous fat thickness and fibre pennation angles will be obtained. Measurements of the viscoelastic properties of the soft tissue above the midpoint of the rectus femoris muscle will be obtained using a myotonometry device (MyotonPro, Tallinn, Estonia).

Anthropometric measures
Anthropometric measures of height, body mass, and waist and hip circumference will be attained in accordance with standard protocols. Bioelectrical impedance analysis performed on an InBody analyser (InBody 370, Chicago, Illinois, USA) will be used to estimate body composition (eg, body fat percentage, fat-free mass).

Survey pack
Participants will be provided with a survey pack containing the following questionnaires:

1. Integrated Palliative Outcome Scale (IPOS-Renal): a validated questionnaire measuring the presence and severity of disease-related symptoms. The IPOS-Renal was developed based on the Palliative Outcome Scale (POS) and IPOS palliative care surveys, but with the additional inclusion of symptoms common in CKD such as pruritus and restless legs.

2. 12-Item Short Form Health Survey (SF-12): a validated 12-item questionnaire used to assess generic health outcomes from the patient’s perspective.

3. Functional Assessment of Chronic Illness Therapy-Fatigue (FACT-F): a validated 13-item multidimensional scale that assesses fatigue over the past 7 days using a 5-point Likert scale that covers physical fatigue,
Habitual physical activity

Objective data on habitual physical activity levels over a 7-day period (ideal minimum 6 days) will be gained from triaxial accelerometers (GENEActiv, ActivInsights, Cambridge, UK). Participants will receive the monitor at the baseline and follow-up assessments and will be asked to wear it from midnight that evening for 7 days.

Blood and urine sampling

Venous blood (30 mL) will be collected using venipuncture of the antecubital vein and prepared and stored appropriately for the following analysis:

- Circulating markers of CVD.
- Circulating markers of systemic inflammation and oxidative stress.
- Blood glucose and HbA1c.
- Lipids and triglycerides.
- Full blood count and renal profile.

A urine sample will be requested to ascertain urinary protein-to-creatinine ratio.

Follow-up assessments

Follow-up visits are summarised in figure 1. An instructional session (or more if required) following baseline assessments will allow the intervention group to become familiar with the exercise requirements and allow the research team to ensure safety and competence before commencing the 12-week, home-based training programme. This can be via video call or in person. At 6 weeks into the 12-week period for the intervention group only, participants will be invited to review exercise progression (via video call or in person), particularly if participants are struggling to undertake the requisite amount of exercise, and as a refresher of the intervention. This combined with regular contact from research staff should aid participant compliance and monitoring.

Final assessments will be conducted for the exercise and control groups within 14 days of completing the 12-week exercise or control period. Assessments completed will be identical to the baseline visit with the addition of a ‘patient satisfaction questionnaire’ to allow pragmatic future development of the study. This will also be offered to participants who withdraw from the trial. Three months after completing the exercise intervention, participants will be contacted for a semistructured one-to-one telephone interview. This will aim to understand the impact of the intervention, if any, on subsequent lifestyle and exercise habits.

Substudies

Additional informed consent will be sought for:

1. Ten ‘healthy’ control participants to undertake a CPET to assess the differences, if any, between CPET parameters in ‘healthy controls’ versus KTRs, particularly during the recovery period.
2. KTRs completing the exercise intervention will be invited to undertake a semistructured interview (via telephone, video call or in person) incorporating exercise self-efficacy, enjoyment, difficulties encountered, perceived advantages and disadvantages of the intervention and study design. Participants who withdraw before the end of the intervention will also be invited to attend, although in line with ethical standards, this will be optional.

Sample size

The purpose of this pilot study is to obtain appropriate data to adequately power future definitive trials; a power calculation is neither relevant nor possible. A minimum sample size of 50 is based on accepted values to provide adequate estimates of SDs for future power calculations.

Data collection and management

Data from all time points will be collected in case report forms (CRFs) by the trial team. All data will be entered into a secure database and will only be accessible on password-protected computers at UHL and University of Leicester by relevant members of the study team. No identifying information will be kept in electronic form. All source data and original participant identities will be kept in a locked office in the trial site file only at UHL.

Data analysis

Data will be assessed for normality using histograms, the Shapiro-Wilk test and Q-Q plots; continuous data to be expressed as mean (±SD) if normally distributed, or median (IQR) if not. To investigate the differences between interventions we will use analysis of (co-)variance. Independent samples t-tests and Mann-Whitney U...
tests will be used assess for baseline differences between variables for normally and non-normally distributed data, respectively. These data will be used to inform the power calculation for future definitive trials.

Qualitative data will be transcribed verbatim and analysed according to the principles of interpretive thematic analysis to explore themes emerging from patient journeys through, and experiences of, the interventions and outcome measures.

Outcomes pertaining to the feasibility of the intervention and trial will be assessed and include:

- **Eligibility**: the percentage of patients screened who are eligible.
- **Recruitment rate**: the percentage of patients eligible who consent to the trial and the monthly recruitment rate.
- **Adherence to the exercise intervention**: the number of completed sessions per week and specific intensity and durations achieved.
- **Acceptability of randomisation**: comparison of the final group characteristics and identification of any stratification variables, if applicable.
- **Attrition rate**: the number of participants who drop out of the study.
- **Outcome acceptability**: the percentage of missing data for each outcome measure.
- **Safety**: the number of self-reported injuries or AEs throughout the trial. The a priori thresholds for specific feasibility and acceptability criteria are as follows: eligibility (≥50%), recruitment success of 20% of eligible participants (≥2 participants per month), adherence (an average of three exercise sessions per week) and attrition (≤30%).

### Safety reporting

All AEs or adverse reactions (ARs) and serious adverse events (SAEs) or serious adverse reactions (SARs) will be recorded from the time a patient enters the study to the final study visit. Each AE or AR will be considered for severity, causality and expectedness and may be reclassified as an SAE or SAR if required.

An SAE is any AE that:

- Is life threatening.
- Requires hospitalisation or prolongation of a hospital admission.
- Results in a persistent or significant disability/incapacity.
- Is a congenital anomaly.
- Results in death.

All AEs and ARs will be documented in participants’ CRFs, medical notes and an AE log, and will record the following information: description, date of onset and end date, severity, assessment of relatedness to study, other suspect device and action taken. Only AEs that are judged to be related to the study intervention or procedures will be reported to the sponsor.

All SAEs will be reported by the investigators to the sponsor within 24 hours of discovery or notification and the report will be signed by the chief investigator within 7 days. If the SAE is deemed related to the research procedures or intervention and is unexpected, a report will be sent to the Research Ethics Committee (REC) within 15 days.

### Patient and public involvement

A patient and public involvement (PPI) group has been convened and will meet with the research team to review progress and address issues that arise throughout the duration of the study. The PPI partners will assist in the interpretation and dissemination of results. The trial was designed in consultation with PPI partners who advised on intervention content and outcome measure acceptability, paying particular attention to patient burden, ensuring outcome measures would not overburden participants. The PPI group approved the final design and duration of this intervention and advised the inclusion of an initial supervised intervention familiarisation period to build confidence in exercise capability.

### Changes to the study protocol following the COVID-19 pandemic

The COVID-19 pandemic has made us all review the ways we design and deliver clinical studies. While patient safety remains the absolute priority of clinical and research teams, there is a need for research to continue in a safe way that balances the benefits of continuing programmes of research against the risks from COVID-19. We have amended the study protocol in several ways to reduce any additional exposure of patients to clinical environments where COVID-19 may be present:

- We have reduced the number of study visits to a minimum. The original study flow diagram is included in online supplemental file 1. All interim assessments have been removed in the modified protocol (figure 1) and the baseline and final study visits are now wrapped into part of patient clinical care. That is to say, when they attend for their baseline and follow-up study visits they will have their clinical review and clinical blood tests as they would for their normal clinical care with a transplant nephrologist (MG-B), so there is no increase in patient visits to a clinical environment over and above their normal care.
- The original study design included a 2-week face-to-face training period where participants would attend the hospital to learn how to complete the exercises and the exercise programme with a member of the research team. This training period will now be done remotely via videoconferencing, with discussion and feedback over the telephone and using the instructional videos and literature that support the home-based exercise intervention.
- When participants attend for their study visits, departmental procedures have been updated to now include meticulous cleaning of all equipment before and after use, one-way flows of participants to ensure
participants do not mix and the use of personal protective equipment for all staff and participants.

The above changes have been agreed with the local REC and the study sponsor and have allowed recommitment of study recruitment and procedures.

**DISCUSSION**

This pilot study is designed to assess the feasibility of delivering a structured, home-based exercise intervention in KTRs at increased cardiometabolic risk and evaluate the putative effects on cardiovascular structure and functional changes, cardiorespiratory fitness, quality of life, healthcare utilisation, patient activation and engagement with the prescribed exercise programme. It is the first trial to use a pragmatic home-based programme of exercise in this patient group. It is also the first to use CMR to evaluate the structural and functional changes of the heart in this at-risk population.

Qualitative data will provide valuable personal perspectives on the acceptability of this specific exercise programme. Transplant recipients experience complex medical journeys and are likely to have specific unmet needs in the area of exercise and lifestyle. This will be valuable information for future randomised controlled trials (RCTs) and exercise guideline development.

Home-based intervention outcomes are reliant on accurate reporting by participants with regard to frequency, intensity and duration of exercise performed. This under-reporting is often a limitation of unsupervised interventions. We will ensure participants are correctly advised on how to monitor and report their exercise completion throughout the trial and encourage this through telephone communications.

We anticipate that a positive outcome will lead to both an increased understanding of the specific exercise requirements of KTRs and the development of new programmes that promote longer term engendered lifestyle change that can be incorporated into standard practice with much lower financial implications than in-centre supervised rehabilitation.

**ETHICS AND DISSEMINATION**

**Ethical issues**

The University of Leicester is the sponsor for this study (UOL 0714). The protocol was reviewed by the East Midlands-Nottingham 2 REC and was given a favourable opinion (REC reference: 19/EM/0209) on 14 October 2019. Health Research Authority regulatory approval was given on 14 October 2019, and the study was adopted on the National Institute for Health Research portfolio on 26 September 2019. Local governance approval was granted by UHL Research & Innovation on 31 January 2020. This study was prospectively registered with ClinicalTrials.gov (11 October 2019). The first participant was recruited on 9 March 2020. The predicted study end date is 31 December 2022. This manuscript is quotable with the most recent approved protocol (version 6, 26 August 2020). Relevant parties will be informed of any substantial protocol modifications. Steps have been taken when designing this protocol to minimise the ethical implications and ensure patient welfare. The study will comply with the International Conference for Harmonisation of Good Clinical Practice guidelines and the Research Governance Framework for Health and Social Care.

**Dissemination**

On completion, the results of this study will be published in peer-reviewed journals and presented at national and international conferences. Contributions of all authors to manuscripts arising from this study will be made explicit in the relevance of each individual journal. Participant-level data will be available following publication of results on request to the chief investigator. Results will also be disseminated to the patient and public community via social media and newsletter articles and presentations at patient conferences and forums, led by the patient partners. It is anticipated that the results of this study will inform future design of larger RCTs in this subject area and contribute to future specific physical activity guidelines in this population.

**Author affiliations**

1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
2John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK
3Department of Health Sciences, University of Leicester, Leicester, UK
4School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
5Department of Radiology, University Hospitals of Leicester NHS Trust, Leicester, UK
6School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
7Centre for Renal and Transplant Research, Westmead Hospital, Westmead, New South Wales, Australia

**Twitter** Roseanne E Billany @RBillany and Sherna F Adenwalla @SAdenwalla

**Acknowledgements** This research is supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Contributors** REB and MG-B: study design, study set-up, completion of study visits, drafting of manuscript, revision of manuscript, finalising of manuscript. NCB, TJW, ACW, SFA, KAR, KC, EMB, NJC, JB, GPM, JOB, ACS: study design, drafting of manuscript, revision of manuscript, completion of study visits, drafting of manuscript, revision of manuscript.

**Funding** This study was funded by a project grant from Kidney Research UK (ref: KS_RP_003_20180913).

**Disclaimer** Neither the sponsor nor the funder had or will have any input into study design; collection, management, analysis and interpretation of data; writing of the report; or the decision to submit the report for publication. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content
includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access: This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Rosenme E Billany http://orcid.org/0000-0001-9610-4717
Angela C Webster http://orcid.org/0000-0001-7509-0512
Matthew PM Graham-Brown http://orcid.org/0000-0002-6197-180X

REFERENCES
1. Oniscu GC, Brown H, Forsythe JLR. How great is the survival advantage of transplantation over dialysis in elderly patients? Nephrol Dial Transplant 2004;19:945–51.
2. Steenkamp R, Rao A, Fraser S. UK renal registry 18th annual report (December 2015) chapter 5: survival and causes of death in UK adult patients on renal replacement therapy in 2014: national and Centre-specific analyses. Nephron. 2016;111:44.
3. Neale J, Smith AC. Cardiovascular risk factors following renal transplant. World Transplant J 2015;5:183-95.
4. UK Renal Registry (2020) UK renal registry 22nd annual report data to 31/10/2018, Bristol, UK. Available: renal.org/audit-research/annual-report
5. Kasikse B, Guljarro C, Massay ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996;7:158–65.
6. Carpenter MA, John A, Weir MR, et al. Bp, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial. J Am Soc Nephrol 2014;25:1554–62.
7. Mail G, Hutter W, Schneider J, et al. Diffuse inflammatorycytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990;5:39-44.
8. Balci RS, Afzali B, Covia A. Cardiomyopathy in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant 2004;18:201–4.
9. Liebelt L, Buddle K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant Intern 2010;23:191-204.
10. Van Lanoce S, Malfray T, Schepers E, et al. Cardiovascular disease after transplantation: an emerging role of the immune system. Transplant Intern 2018;31:889-99.
11. Weiner DE, Tighiouart H, Elsayy EF, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007;50:217-24.
12. Aalten J, Peeters SA, van der Vlugt MJ, et al. Is standardized cardiovascular assessment of asymptomatic high-risk renal transplant candidates beneficial? Nephrol Dial Transplant 2011;26:3006-12.
13. Mansell H, Rosasen N, Dean J, et al. Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores. Clin Transplant 2013;27:E391-9.
14. Mansell H, Stewart SA, Shoker A. Validity of cardiovascular risk prediction models in kidney transplant recipients. ScientificWorldJournal 2014;2014:750579.
15. Devine PA, Courtney AE, Maxwell AP. Cardiovascular risk in renal transplant recipients. J Nephrol 2019;32:389-99.
16. Kasikse B, Epidemiology of cardiovascular disease after renal transplantation. Transplant Intern 2001;13:25-8.
17. de Albuquerque Suassuna PG, Sanders-Pinheiro H, de Paula RB. Uremic cardiomyopathy: a new piece in the chronic kidney Disease-Mineral and bone disorder puzzle. Front Med 2015;2:206-06.
18. Aoki J, Ikari Y, Nakajima H, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Intern 2005;67:333-40.
19. Mark PB, Doyle A, Blyth KG, et al. Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease. J Cardiovasc Magn Reson 2008;10:39.
20. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Intern 1995:47:186-92.
21. Foley RN, Parfrey PS, Harnett JD, et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-31.
handgrip strength measurement in clinical and epidemiological studies of kidney disease: toward a standardized approach. J Ren Nutr 2021. doi:10.1053/j.jrn.2021.06.005. [Epub ahead of print: 19 Jul 2021].

Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142–8.

Hadijoannou I, Wong K, Lindup H, et al. Test-retest reliability for physical function measures in patients with chronic kidney disease. J Ren Care 2020;46:25–34.

Wilkinson TJ, Terrell D, Smith AC. Postural stability during standing and its association with physical and cognitive functions in non-dialysis chronic kidney disease patients. Int Urol Nephrol 2019;51:147–17.

Eston RG, Reilly T. Kinanthropometry and exercise physiology laboratory manual: tests, procedures, and data. 3rd ed. Abingdon: Routledge; 2009.

Chertow GM, Lowrie EG, Wilmore DW, et al. Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients. J Am Soc Nephrol 1995:56:75–81.

Macdonald JH, Marcova SM, Libani M, et al. Bioelectrical impedance can be used to predict muscle mass and hence improve estimation of glomerular filtration rate in non-diabetic patients with chronic kidney disease. Nephrol Dial Transplant 2006;21:3419–21.

Roy J, Ahuja K, Franssen M, et al. Validation of the IPOS-Renal symptom survey in advanced kidney disease: a cross-sectional study. J Pain Symptom Manage 2018;56:281–7.

Ware J, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.

Wang S-Y, Zhang X-Y, Liu J-D, et al. Psychometric properties of the functional assessment of chronic illness therapy-fatigue (FACT-Fatigue) in Chinese patients receiving maintenance dialysis. J Pain Symptom Manage 2015;49:135–43.

Yellen SB, Celia DF, Webster K, et al. Measuring fatigue and other domain-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63–74.

Buyske DJ, Reynolds CF, Monk TH, et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.

Billany JH, Stockard J, Mahoney ER, et al. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 2004;39:1005–26.

Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med 2004;36:588–94.

Cavanaugh KL, Osborn CY, Tentori F, et al. Performance of a brief survey to assess health literacy in patients receiving hemodialysis. Clin Kidney J 2015;8:462–8.

Dagforde LA, Cavanaugh KL, Moore DE, et al. Validation of the written administration of the short literacy survey. J Health Commun 2015;20:835–49.

Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health 2009;6:790–804.

Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke activity status index). Am J Cardiol 1989;64:651–4.

Dillon CB, Fitzgerald AP, Kearney PM, et al. Number of days required to estimate habitual activity using Wrist-Worn GENActiv Accelerometer: a cross-sectional study. PLoS One 2016;11:e0169913.

Moore CG, Carter RE, Niertet PJ, et al. Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci 2011;4:332–7.

Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol 2012;65:301–8.

Gordon EJ, Prohaska T, Siminoff LA, et al. Needed: tailored exercise regimens for kidney transplant recipients. Am J Kidney Dis 2005;45:769–74.